Asahi Kasei Pharma America Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
19
- Latest Deal Type
-
M&A
Asahi Kasei Pharma America General Information
Description
Provider of critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. The company offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis.
Contact Information
Corporate Office
- 200 Fifth Avenue
- 6th Floor
- Waltham, MA 02451
- United States
Corporate Office
- 200 Fifth Avenue
- 6th Floor
- Waltham, MA 02451
- United States
Asahi Kasei Pharma America Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 28-Nov-2011 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series C) | 20-Jul-2010 | Completed | Startup | |||
| 3. Early Stage VC (Series B) | 01-Mar-2010 | Completed | Startup | |||
| 2. Early Stage VC | 20-Jan-2010 | $15.4M | $54.4M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 06-Sep-2006 | $39M | $39M | Completed | Startup |
Asahi Kasei Pharma America Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 22,000,000 | $0.001000 | 6% | $2 | $2 | 1x | $1.83 | 43.78% |
Asahi Kasei Pharma America Patents
Asahi Kasei Pharma America Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240366505-A1 | Liquid resin extended-release oral naltrexone formulation for treating autism-related disorders | Pending | 26-Jan-2022 | ||
| US-20250134883-A1 | Novel compositions | Pending | 26-Jan-2022 |
Asahi Kasei Pharma America Signals
Asahi Kasei Pharma America Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Asahi Kasei Corporate Venture Capital | Corporate Venture Capital | Minority | ||
| Bio*One Capital | Corporate Venture Capital | Minority | ||
| EDBI | Venture Capital | Minority | ||
| IQVIA Holdings | Corporation | Minority | ||
| Jafco | Venture Capital | Minority |
Asahi Kasei Pharma America FAQs
-
When was Asahi Kasei Pharma America founded?
Asahi Kasei Pharma America was founded in 2006.
-
Where is Asahi Kasei Pharma America headquartered?
Asahi Kasei Pharma America is headquartered in Waltham, MA.
-
What is the size of Asahi Kasei Pharma America?
Asahi Kasei Pharma America has 19 total employees.
-
What industry is Asahi Kasei Pharma America in?
Asahi Kasei Pharma America’s primary industry is Pharmaceuticals.
-
Is Asahi Kasei Pharma America a private or public company?
Asahi Kasei Pharma America is a Private company.
-
What is Asahi Kasei Pharma America’s current revenue?
The current revenue for Asahi Kasei Pharma America is .
-
How much funding has Asahi Kasei Pharma America raised over time?
Asahi Kasei Pharma America has raised $79.6M.
-
Who are Asahi Kasei Pharma America’s investors?
Asahi Kasei Corporate Venture Capital, Bio*One Capital, EDBI, IQVIA Holdings, and Jafco are 5 of 7 investors who have invested in Asahi Kasei Pharma America.
-
When was Asahi Kasei Pharma America acquired?
Asahi Kasei Pharma America was acquired on 28-Nov-2011.
-
Who acquired Asahi Kasei Pharma America?
Asahi Kasei Pharma America was acquired by Asahi Kasei.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process